IPAMORELIN 2000mcg

Ipamorelin 2000mcg Peptide for In Vitro Research – Ipamorelin is a powerful synthetic hexapeptide renowned for its ability to stimulate growth hormone release in animal studies.^1,2 Acting on the growth hormone secretagogue receptor (GHS-R), ipamorelin releases growth hormone from the anterior pituitary cells, which has been linked to body weight gain and growth in laboratory settings. Research shows that ipamorelin has pharmacological effects comparable to ghrelin, though with a unique structure, making it a key compound in growth hormone and peptide research.³

In animal models, ipamorelin peptide has demonstrated efficacy in supporting bone growth and structure. In an 8-week study, ipamorelin, growth hormone, and other peptides were assessed for their effects on bone growth. Results indicated that ipamorelin significantly increased bone mineral content, with its bone-stimulating effects surpassing other peptides while being slightly less effective than direct growth hormone.³

One of ipamorelin’s unique advantages in research is its target-specificity: unlike other growth hormone secretagogues, it does not elevate adrenocorticotropic hormone (ACTH) or cortisol levels in animals.¹ Additionally, ipamorelin does not affect the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, or thyroid-stimulating hormone (TSH), making it highly selective and ideal for targeted in vitro research.

Ipamorelin has also been investigated for its potential in diabetes research. In studies, ipamorelin has been found to increase insulin-like growth factor (IGF-I) and enhance insulin release in both diabetic and non-diabetic animal models. This suggests a potential research application for understanding insulin regulation and diabetes-related peptide studies.⁴

Product Information: Ipamorelin is available as a lyophilized white powder in a 2000 mcg vial, intended exclusively for in vitro laboratory research and is not for use in humans or animals outside of research environments.

References:
1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.
2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone-releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6.
3. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77.
4. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6.